BioNote Inc
KRX:377740
BioNote Inc
Current Portion of Long-Term Debt
BioNote Inc
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
B
|
BioNote Inc
KRX:377740
|
Current Portion of Long-Term Debt
â‚©1.3B
|
CAGR 3-Years
113%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Celltrion Inc
KRX:068270
|
Current Portion of Long-Term Debt
â‚©175.7B
|
CAGR 3-Years
40%
|
CAGR 5-Years
27%
|
CAGR 10-Years
-1%
|
||
SK Bioscience Co Ltd
KRX:302440
|
Current Portion of Long-Term Debt
â‚©8.1B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
||
H
|
Hugel Inc
KOSDAQ:145020
|
Current Portion of Long-Term Debt
â‚©2.7B
|
CAGR 3-Years
20%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Current Portion of Long-Term Debt
â‚©23.6B
|
CAGR 3-Years
71%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
Alteogen Inc
KOSDAQ:196170
|
Current Portion of Long-Term Debt
â‚©88.9B
|
CAGR 3-Years
11%
|
CAGR 5-Years
297%
|
CAGR 10-Years
N/A
|
BioNote Inc
Glance View
BioNote, Inc. develops veterinary diagnostic composition. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2022-12-22. The firm is engaged in the manufacture and sale of rapid diagnostic kits for humans, diagnosis raw materials such as antigens, antibody cell lines, standards, enzymes and others as well as semi-finished products. The firm is also engaged in the manufacture and sale of rapid immunochemical diagnosis, enzyme immune rebound protein, immunochemical fluorescence diagnosis and other products used for animals.
See Also
What is BioNote Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
1.3B
KRW
Based on the financial report for Dec 31, 2023, BioNote Inc's Current Portion of Long-Term Debt amounts to 1.3B KRW.
What is BioNote Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
113%
Over the last year, the Current Portion of Long-Term Debt growth was 185%. The average annual Current Portion of Long-Term Debt growth rates for BioNote Inc have been 113% over the past three years .